Hypera Pharma
Hypera Pharma, a leading player in the Brazilian pharmaceutical industry, is headquartered in São Paulo, Brazil. Founded in 2010, the company has rapidly established itself as a key provider of prescription and over-the-counter medications, focusing on therapeutic areas such as central nervous system disorders, dermatology, and consumer health. With a diverse portfolio of well-known brands, Hypera Pharma distinguishes itself through its commitment to innovation and quality, ensuring that its products meet the highest standards. The company has achieved significant market presence, becoming one of the largest pharmaceutical companies in Brazil, and has garnered recognition for its strategic acquisitions and robust growth trajectory. Hypera Pharma continues to enhance its position in the industry by prioritising research and development, aiming to improve health outcomes for patients across the region.
DitchCarbon Score
How does Hypera Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hypera Pharma's score of 11 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hypera Pharma's reported carbon emissions
Hypera Pharma's carbon emissions data reveals a significant environmental footprint, with total emissions reaching approximately 50,202,930 kg CO2e in 2021. This figure includes 25,417,550 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 8,665,850 kg CO2e from Scope 2 emissions, related to purchased electricity. Additionally, Scope 3 emissions, which account for indirect emissions in the value chain, totalled about 16,119,530 kg CO2e. In the preceding years, emissions have fluctuated, with 2020 reporting approximately 44,803,470 kg CO2e, 2019 at about 24,095,660 kg CO2e, and 2018 showing around 19,561,440 kg CO2e. Notably, the increase from 2020 to 2021 indicates a rising trend in emissions, particularly in Scope 1 and Scope 2 categories. Despite the substantial emissions figures, there are currently no publicly disclosed reduction targets or climate pledges from Hypera Pharma. This absence of specific commitments highlights a potential area for improvement in their sustainability strategy. As the pharmaceutical industry increasingly prioritises climate action, Hypera Pharma may benefit from establishing clear reduction goals aligned with global standards to enhance its environmental performance and reputation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Scope 1 | 19,561,440 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 4,925,500 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 17,458,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hypera Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
